Innate Pharma SA Price to Free Cash Flow Ratio 2012-2023 | IPHYF

Innate Pharma SA price to free cash flow ratio from 2012 to 2023. Price to free cash flow ratio can be defined as

Innate Pharma SA Price to Free Cash Flow Ratio 2012-2023 | IPHYF

Innate Pharma SA price to free cash flow ratio from 2012 to 2023. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$77.1B
Chugai Pharmaceutical (CHGCY)$71.1B
Takeda Pharmaceutical (TAK)$42.6B
Sandoz Group AG (SDZNY)$21B
Merck (MKKGY)$19.6B
Astellas Pharma (ALPMY)$17.5B
Summit Therapeutics (SMMT)$15.9B
United Therapeutics (UTHR)$15.7B
Neurocrine Biosciences (NBIX)$15.4B
Shionogi (SGIOY)$13B
Orion OYJ (ORINY)$7.7B
Madrigal Pharmaceuticals (MDGL)$7.3B
Corcept Therapeutics (CORT)$7B
Stevanato Group S.p.A (STVN)$6.8B
Hikma Pharmaceuticals Plc (HKMPF)$5.9B
Ionis Pharmaceuticals (IONS)$5B
Grifols, S.A (GRFS)$4.7B
Ono Pharmaceutical (OPHLF)$4.3B
Crinetics Pharmaceuticals (CRNX)$3.7B
Recursion Pharmaceuticals (RXRX)$2.8B
Catalyst Pharmaceuticals (CPRX)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Centessa Pharmaceuticals (CNTA)$2.2B
Soleno Therapeutics (SLNO)$2.2B
NewAmsterdam Pharma (NAMS)$2.1B
Hypermarcas (HYPMY)$2B
Indivior (INDV)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B
Evotec AG (EVO)$1.6B
Dyne Therapeutics (DYN)$1.4B